is...trading...and investing...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
.10--- we shall see
5ish... is Schroeder gonna await on CAFC now???
As I mentioned, Derek has been getting media attention.
we shall see--- I have not heard from AJ lately... BUT .11 today... and media is covering Derek.
nice up to 11.30 now...
I guess that is the message---NOT here.
But we are down 60%....................
looks good for now
Let's see who they pick for new CEO!
Dunno--- I am just holding now.
We are down 60% so what's the point of selling out.
I am following Derek and AJ.
There has been good media lately with Derek!
So at least there is some interest in that arena!
I also spoke with the TURV lawyer... interesting!
TY, Neal
PTAB decision today. See IV.
PATIENCE IS A VIRTUE
tiger--- ??? did you check??? This deal did not happen I am told:
On July 9, 2019, the Company entered into a Commercial Lease Agreement (the “Lease”) with Skybar Holdings, LLC, a Florida limited liability company. Pursuant to the Lease, the Company will rent the entire first floor (consisting of approximately 4,000 square feet) of a property located in Delray Beach, Florida (the “Premises”). The Company plans to develop the Premises to create a hemp-oriented health and wellness retail venue, including education, clothing and cosmetics, and explore franchise opportunities. The initial term of the Lease is 5 years commencing August 1, 2019, with two 5-year extension options. The Lease includes a right of first refusal in favor of the Company to lease any space that becomes available on the 2nd and 3rd floor of the Premises and a right of first refusal to purchase the Premises. Pursuant to the Lease, the Company will pay rent equal to $40,000 per month in advance in addition to all applicable Florida sales and/or federal taxes and security deposit of $40,000. Effective one year from the lease commencement date and each year thereafter, the rent shall increase at least three percent (3%) per year. The lessor of the Premises is a limited liability company owned or controlled by Vladislav (Bobby) Yampolsky, a member of the Board and the founder, manager and controlling member of C2M, the Company’s largest stockholder.
https://pomerantzlawfirm.com/active-cases-rz/vhc
TY, Neal H. Hurwitz 212-666-6217
...if you are interested as a shareholder
Desert Eagle--- call me pls re Rosalind 212-666-6217.
Thanks! Neal
Sam--- OK, got it! OK.
My conversation with Rosalind was reassuring... They seem to be IN long-term--- years!
Let's see the new CEO coming up soon.
I bought again, which is amazing given my last few shares were $660!!!
Not one question on the call asked--- wow... huh???
No interest???
Chatted with Rosalind.
Interested?: call me 212-666-6217 any time
Neal in NY NY Medellin Israel
Hobbs and the BOD sorta destroyed DCTH with the FDA.
I am trying to speak with Zager in FL. But I think he is silent since the BOD pays him...
Hard to trust anything with this as long as Harold K and Stoll are involved...
I am watching Steve S from Rosalind... he was IN at KTOV when we were...
250KG of CBD isolate delivered to Huntington Beach hospital on 6/26/20 .
At $700/KG??? or?
Was it paid?
Yes... and watch Rosalind.
2020 results could cause a pop === or not.
2021 with FDA--- gotta find out how Pazdur feels about Delcath now.
how much $$$ is that?
sounds quite rational and promising... :) TY! Neal
Why don't you call him and ask him yourself?
bueno, I guess... we put in $10 million to help Ladd against Koly... stock at $60 was super time! :)
I do not like the angry resignation latter from the BOD Member, or the dismissal of the other BOD Member.
Rosalind role???
Harold K and Stoll are still there??? and Zager role now?
Pazdur is still at FDA and he hated DCTH.
TY! I should know from AJ on the 30th.
watch Rosalind!!! sold 51%... WHEN???
watch Rosalind!!!!!!!!!!!!!!!
you left out EA... right? why?
KTOV now 1.12
Richard Pazdur MD
Director of the FDA's Oncology Center of Excellence (OCE), which leverages the combined skills of the FDA's regulatory scientists and reviewers with expertise in drugs, biologics and devices to expedite the development of novel cancer products. In his role as director of the OCE, Pazdur is responsible for leading the effort to develop and execute an integrated regulatory approach to enhance the cross-center coordination of oncology product clinical review.
Pazdur previously served as the director of the Office of Hematology and Oncology Products (OHOP) in the FDA’s Center for Drug Evaluation and Research and will continue to serve in OHOP as acting director. This Office was formed in 2005 to consolidate the review of drugs and therapeutic biologics for the diagnosis, treatment, and prevention of cancer, as well as the review of drugs and therapeutic biologics for hematologic diseases and for medical imaging. As director of OHOP, Pazdur facilitated coordination of oncology activities across all FDA Centers and ensured an ongoing outreach and collaboration between the FDA, the National Cancer Institute, and other cancer-related organizations within and outside of the government. Pazdur was the director of the Division of Oncology Drug Products from September 1999 to May 2005.
Prior to joining the FDA, Pazdur was professor of medicine at The University of Texas M.D. Anderson Cancer Center in Houston, Texas. Pazdur was on the faculty of the M. D. Anderson Cancer Center from 1988 to 1999. During his tenure at the M. D. Anderson Cancer Center, Pazdur held administrative positions of assistant vice president for academic affairs, associate director of clinical trials administration (Division of Medicine) and director of educational programs (Division of Medicine). Pazdur served on the faculty of Wayne State University, Detroit, Michigan from 1982 to 1988.
Pazdur received his bachelor’s degree from Northwestern University (Evanston, Illinois), his M.D. from Loyola Stritch School of Medicine (Maywood, Illinois), and completed clinical training at Rush-Presbyterian St. Luke’s Medical Center (Chicago, Illinois) and the University of Chicago Hospitals and Clinics.
Pazdur has published more than 400 articles, book chapters and abstracts. In 2015, Fortune magazine named Pazdur as one of the 50 World’s Greatest Leaders. The American Association for Cancer Research recognized Pazdur with its Distinguished Public Service Award (2015) and the American Society of Clinical Oncology recognized him with the Service Recognition Award (2009) and the Public Service Award (2013). In 2015, Pazdur also received the Public Service Leadership Award from the National Coalition for Cancer Survivorship and also the Face of Hope Award from the LUNGevity Foundation. Most recently, in 2016, Pazdur was named to Massachusetts General Hospital Cancer Center’s “The One Hundred” list.
###
Pazdur killed DCTH last time out at FDA.
Mr. Purpura stated, “I am excited to guide the Company through a transformative period as we prepare to release top-line data from the Phase 3 FOCUS trial in metastatic ocular melanoma by year-end 2020 and resubmit our NDA next year.”
###
Two events of importance.
Year end is 12/20.
FDA approval possible 2021.
IS PAZDUR still at FDA??? He hated Hobbs and DCTH last time at FDA. We were there: 16-0 'fixed' results against DCTH.
Quite often, you have to pay talent.
OTOH--- can they succeed?---
FOR US SHAREHOLDERS?
I will take $150K and stock too!!! :)
AJ has been VERYYYY busy.
Call Steve Salomon now on the BOD in Toronto--- he is Rosalind.
R did this with KTOV.
I sent your post to AJ for response to me. TY, Neal
Let's also see about the $900K orders in Q1.
"I know the new Chairman."--- No, you do not. Be careful of misstatements. I saw your correction.
Just be more careful. There is a lot at stake here now.
Thanks!--- looks clean and good.
I will discuss with AJ manana.